A practical reference on lyophilised powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Common degradation pathways include oxidation of the methionine side chain, hydrolysis of the peptide backbone, and aggregation under unfavourable pH or concentration. Stability studies typically monitor the main peak by chromatography and report total related substances as a percentage. Because no official monograph exists, acceptance criteria vary between laboratories, and reported purity values are not directly comparable across suppliers. Analysts therefore document the method, column, and detection wavelength alongside each result, and open questions remain about how much biological activity the oxidised forms retain.
Solid semax is typically supplied as a lyophilised powder that is hygroscopic and sensitive to moisture, light, and repeated temperature cycling. Long-term storage of the dry peptide is generally recommended at approximately -20 degrees Celsius, while shorter working periods may use refrigeration at 2 to 8 degrees Celsius. Vials should remain tightly closed and desiccated when brought to room temperature, because condensation can damage the material before it is weighed. Dividing a batch into aliquots is preferable to thawing one container repeatedly.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid from research suppliers |
| Solubility | Freely soluble in water | Also dissolves in aqueous buffers; solutions are used fresh |
| Typical storage temperature | -20 °C for lyophilized powder | Short-term transport at 2-8 °C is common |
| Common analytical method | Reverse-phase HPLC | Paired with mass spectrometry for identity confirmation |
| Common synonyms | ACTH(4-10) analogue; MEHFPGP | N-terminal methionine retained in the chain |
Identity and purity are confirmed with reversed-phase high-performance liquid chromatography, typically monitored at 214 nanometres where the peptide bond absorbs. Mass spectrometry, either electrospray or MALDI-TOF, verifies molecular mass against the theoretical value and detects truncation or adduct formation. Amino acid analysis and peptide mapping provide additional confirmation when required. The most frequently reported impurities are deletion sequences from incomplete coupling, methionine sulfoxide from oxidation, and dimeric species formed through non-covalent aggregation. Impurity profiles depend strongly on the synthesis and purification route chosen by the producer.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
Semax is normally supplied as a lyophilized powder, and that form is the most stable. Suppliers commonly recommend storage at -20 °C in a desiccated container protected from light, with short-term handling at room temperature limited to weighing and transfer. Powder that has absorbed moisture degrades faster, so vials should be warmed to ambient temperature before opening to prevent condensation on the contents. Hygroscopic behavior is typical of short hydrophilic peptides, and humidity control matters more than temperature alone for long-term retention.
Once dissolved, the peptide is considerably less stable than the solid. Aqueous solutions are usually prepared at neutral to slightly acidic pH, filtered, and divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are a common cause of avoidable loss and are best prevented by never refreezing a thawed aliquot. Adsorption to plastic and glass surfaces can lower the measured concentration of dilute solutions, particularly below roughly 0.1 mg/mL. Buffer choice, salt content, and container material all influence how much peptide remains detectable after storage.
Identity and purity are established with standard peptide methods. Reversed-phase HPLC with ultraviolet detection near 214 nm resolves the parent peak from deletion and truncation byproducts, and reports typically quote a main-peak percentage. Mass spectrometry by electrospray or MALDI-TOF confirms the expected molecular mass, while amino acid analysis or peptide mapping can verify composition when the sequence itself is in question. A certificate of analysis that pairs a chromatogram with a mass spectrum is more informative than a purity figure alone. Counter-ion content and residual solvents are separate specifications and are frequently omitted.
a DNA template that contains the DNA target region to amplify a DNA polymerase; an enzyme that polymerizes new DNA strands; heat-resistant Taq polymerase is especially common, as it is more likely to remain intact during the high-temperature DNA denaturation process. Pfu polymerase is a heat-resistant polymerase with higher accuracy compared to Taq due to its ability to proofread, but it runs slower. Adding a small amount of Pfu to Taq combines the benefits of both.
Solanine is a glycoalkaloid poison found in species of the nightshade family within the genus Solanum, such as the potato (Solanum tuberosum). It can occur naturally in any part of the plant, including the leaves, fruit, and tubers. Solanine has pesticidal properties, and it is one of the plant's natural defenses. Solanine was first isolated in 1820 from the berries of the European black nightshade (Solanum nigrum), after which it was named. It belongs to the chemical family of saponins.
=== Criticism of expert witnesses === Several medical experts have questioned the reliability of the prosecution's expert witness, Dewi Evans. Svilena Dimitrova, an NHS consultant neonatologist, and Roger Norwich, a medico-legal expert, submitted formal complaints to the General Medical Council regarding Evans's evidence. Dimitrova told The Guardian that she believed "the theories proposed in court were not plausible and the prosecution was full of medical inaccuracies", adding that while she could not assert Letby's innocence, she saw "no proof of guilt". Evans rejected suggestions of bias and noted that the defence could have called its own expert witnesses at trial but did not do so. Other prosecution experts broadly supported Evans' conclusions. The New Yorker reported that in an unrelated earlier case, a Court of Appeal judge had described one of Evans's expert reports as "worthless", containing opinions that were "tendentious and partisan" and outside his professional competence. Another paediatrician who testified as an expert for the prosecution has since resigned from her position as a consultant following multiple complaints about her practice. The prosecution's endocrinologist, Peter Hindmarsh, was under investigation by the General Medical Council (GMC) when he gave evidence during the trial. The investigation was prompted by "multiple and wide-ranging concerns" about his practice from both of the hospitals he was affiliated with. A medical tribunal placed restrictions on his ability to practise, arguing that he "may pose a real risk to members of the public".
Sources: en.wikipedia.org
As booster vaccines for COVID-19 were rolled out in New Zealand early in 2022 with the wait time between the second and third doses shortened to three months, Turner responded to several suggestions about this. She refuted that the booster needed to be in the non-dominant arm, noting while it was good to keep fluid levels up during heat, drinking water, [won't] "make any difference to the vaccine response" and while stress on the immune system was understandable, there was little cause for concern. When the New Zealand government announced in May 2022 that there would be a second COVID-19 booster available to some members of the community, Turner expressed concern about the low rate of uptake for the first booster..."particularly the lower rate of boosters for older people and those with medical conditions...[adding]..."but still, there are quite a few people who feel like two doses aren't enough, and don't realise the importance of a booster". In November 2022, when parents of a four-month-old baby in New Zealand who needed heart surgery requiring a blood transfusion refused to accept blood from a donor who had received the COVID-19 vaccine, Turner said there was no scientific evidence suggesting there would be any risk to the baby. She noted [that] "blood donations are carefully screened for safety to ensure it was a match for the recipient", and people with concerns about this should talk to a professional.
=== Electrochemical synthesis === Electrochemical synthesis can exfoliate graphene. Varying a pulsed voltage controls thickness, flake area, and number of defects and affects its properties. The process begins by bathing the graphite in a solvent for intercalation. The process can be tracked by monitoring the solution's transparency with an LED and photodiode.
==== Research and traditional medicine ==== Preliminary research indicates that the phytochemicals, betulin and possibly other triterpenes, are active in Episalvan gel and wound healing properties of birch bark. Over centuries, birch bark was used in traditional medicine practices by North American indigenous people for treating superficial wounds by applying bark directly to the skin. Splints made with birch bark were used as casts for broken limbs in the 16th century.
When circulating in the plasma (plasma fatty acids), not in their ester, fatty acids are known as non-esterified fatty acids (NEFAs) or free fatty acids (FFAs). FFAs are always bound to a transport protein, such as albumin. FFAs also form from triglyceride food oils and fats by hydrolysis, contributing to the characteristic rancid odor. An analogous process happens in biodiesel with risk of part corrosion.
Sources: en.wikipedia.org
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.
A fraction of an intranasal dose is thought to reach the central nervous system, and this route is favoured partly for that reason. The proportion is not well characterized. Direct measurement in humans remains difficult with current methods.
Raised BDNF and NGF expression has been reported across several animal studies, which makes the signal fairly consistent. Whether the same change occurs in humans at usable doses is not established. It is best treated as a working hypothesis rather than a confirmed clinical mechanism.
Dry powder is usually kept at about -20 degrees Celsius for long-term storage and at 2 to 8 degrees Celsius for short working periods. Containers should stay sealed and protected from light and moisture to limit degradation.